Market Place
Sourcing Support
Ashvattha Presents Neuroinflammation Imaging/Treatment Candidates At SNMMI
10 Jun 2024 //
GLOBENEWSWIRE
Ashvattha Theranostics Preclinical Data: Cmsc Snmmi 2024 Meetings Featured
23 May 2024 //
GLOBENEWSWIRE
Ashvattha Announces First Patient Enrolled in Phase 1/2 Study of 18F-OP-801
22 Feb 2024 //
GLOBENEWSWIRE
Ashvattha Therapeutics to Participate in Upcoming Investor Conferences
14 Feb 2024 //
GLOBENEWSWIRE
Ashvattha Announces the Appointment of Mehdi Paborji as Senior Vice President
04 Jan 2024 //
GLOBENEWSWIRE
Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences
20 Nov 2023 //
GLOBENEWSWIRE
Ashvattha Announces First Patient Dosed of Anti-Angiogenic Therapeutic D-4517.2
01 Nov 2023 //
GLOBENEWSWIRE
Ashvattha Announces Appointment of Dr. Sakura Minami as Vice President
09 Oct 2023 //
GLOBENEWSWIRE
Ashvattha Therapeutics Presents Promising Preclinical Data on ASH41020
22 Aug 2023 //
GLOBENEWSWIRE
Ashvattha Announces Presentation of Data on Dendranib Nanomedicine Candidate
15 Aug 2023 //
GLOBENEWSWIRE
Ashvattha Appoints Paul E. Cayer as CFO and Mahesh Karande to Board of Directors
31 May 2023 //
GLOBENEWSWIRE
Ashvattha Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2
26 Apr 2023 //
GLOBENEWSWIRE
Ashvattha Therapeutics Presented Promising Preclinical Data on Novel Macrophage
18 Apr 2023 //
GLOBENEWSWIRE
Ashvattha to Present Preclinical Data at AACR and ARVO 2023 Annual Meetings
03 Apr 2023 //
GLOBENEWSWIRE
Ashvattha Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801
06 Feb 2023 //
GLOBENEWSWIRE
Ashvattha Therapeutics to Present at Upcoming Investor Conferences
02 Feb 2023 //
GLOBENEWSWIRE
Ashvattha Therapeutics to Present at Biotech Showcase 2023
03 Jan 2023 //
GLOBENEWSWIRE
Ashvattha Announces the Appointment of Steve Maricich as Chief Medical Officer
20 Oct 2022 //
GLOBENEWSWIRE
Ashvattha Announces Preclinical Data on Hydroxyl Dendrimer Based PET
29 Sep 2022 //
GLOBENEWSWIRE
Ashvattha Therapeutics Announces Presentations of Preclinical Data
15 Sep 2022 //
GLOBENEWSWIRE
Ashvattha Announces First Patient Enrolled in a Phase 2 Study of D-4517.2
07 Sep 2022 //
GLOBENEWSWIRE
Ashvattha previews plans for long Covid trial in mid-2023
11 Aug 2022 //
CLINICALTRIALSARENA
Ashvattha Therapeutics Announces Preclinical Data at the 2022 AAIC of OP-801
01 Aug 2022 //
GLOBENEWSWIRE
Ashvattha to publish Data in STM from PIIa Trial for OP-101 in Severe COVID-19
25 Jul 2022 //
GLOBENEWSWIRE
Ashvattha Tx to Present Poster PC Data on [18F]OP-801 at the 2022 AAIC
18 Jul 2022 //
GLOBENEWSWIRE
Ashvattha Announces Poster Presentation of Data on Hydroxyl Dendrimer-Based Tx
07 Jun 2022 //
GLOBENEWSWIRE
Ashvattha Therapeutics to Present at UBS Global Healthcare Conference 2022
05 May 2022 //
GLOBENEWSWIRE
Ashvattha Presents Phase 1 Safety Data in Subcutaneous anti-VEGF wet AMD and DME
02 May 2022 //
GLOBENEWSWIRE
Ashvattha Therapeutics Announces $69M in Series B Financing and up to $45M ELA
27 Apr 2022 //
GLOBENEWSWIRE
Ashvattha Tx Announces Key Executive Appointments
01 Mar 2022 //
BUSINESSWIRE
Ashvattha Therapeutics Announces Participation at Upcoming Investor Conferences
09 Sep 2021 //
BUSINESSWIRE
Ashvattha Announces Interim Data from Phase 2 PRANA Clinical Study of OP-101
15 Jun 2021 //
BUSINESSWIRE
Ashvattha Presents Transformative Anti-Angiogenesis Treatment RD
26 Apr 2021 //
BUSINESSWIRE
Ashvattha Presents Transformative Anti-Angiogenesis Treatment ARVO 2021
26 Apr 2021 //
BUSINESSWIRE
Ashvattha Therapeutics Announces Attendance at Upcoming Investor Conferences
18 Feb 2021 //
BUSINESSWIRE
Ashvattha Therapeutics Announces Collaboration With Stanford University OP-801
14 Dec 2020 //
BUSINESSWIRE
Ashvattha Selected to Present Late-Breaking Poster Presentation
02 Nov 2020 //
BUSINESSWIRE
Ashvattha Therapeutics Appoints Industry Veteran George G. Montgomery
07 Oct 2020 //
BUSINESSWIRE
